AUREA Trial’s Decisive 90 Days: DAPT Shows Advantage Over OAC in Cerebral Protection post-TAVI?
EuroIntervention, an official Journal of Euro PCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), recently shareda post on X:
”In this randomized trial, OAC did not outperform DAPT in preventing cerebral microembolism post-TAVI. DW-MRI findings suggest DAPT may lead to lower total embolic volume at 90 days.”
Read the article here.
EuroInterention recently shared the AUREA trial data on use of OAC and DAPT: ‘A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial‘ published by Victor Alfonso Jimenez Diaz et al.
In the AUREA randomized clinical trial evaluating post-TAVI antithrombotic strategies, oral anticoagulation (OAC) did not outperform dual antiplatelet therapy (DAPT) in preventing cerebral microembolism.
Among patients without a formal indication for anticoagulation, a 3-month OAC regimen failed to demonstrate benefit over DAPT in reducing subclinical brain infarcts.
Diffusion-weighted MRI at 90 days revealed a lower mean embolic volume in patients receiving DAPT compared to those on acenocoumarol, suggesting DAPT may offer superior cerebral protection in this population.
Hemostasis Today, daily news on stroke management.
-
Aug 26, 2025, 10:02Women’s Equality Day: HFA Recognizes Women with Bleeding Disorders
-
Aug 26, 2025, 09:59Rare Disease Advisor – RBC Rheology Alterations in Hemophilia with Arthropathy
-
Aug 26, 2025, 09:57HFA Supports Future Planning for People with Bleeding Disorders
-
Aug 26, 2025, 09:56Phillip Taboada: TXA Shows No Added Benefit in Aquablation
-
Aug 26, 2025, 09:50A Global Collaboration: PERT Consortium Expands Reach in PE Care
-
Aug 26, 2025, 09:54TSUBASA Study: Emicizumab Improves Daily Life and Motivation in Hemophilia A Patients
-
Aug 26, 2025, 09:38Advancing CAT Care: New Insights on Extended Anticoagulation from Gerotziafas and Tafur
-
Aug 26, 2025, 09:35Alexander Mazein: Innovative Insights into Cytokine Release Syndrome via a Novel Explorable Model for Biotherapeutics and Cellular Therapies
-
Aug 25, 2025, 10:40Maria Filomena Ruberto on The Hypercoagulable State
-
Aug 25, 2025, 09:19Parham Dastjerdi – Clonal Hematopoiesis and VTE Risk
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!